Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01399684 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 127
- Enrollment target
NCT01399684 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 127 participants.
The verdict
NCT01399684, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 127 participants
- Enrollment target
Study Summary
This is a Phase II, multicenter, randomized, double-blind, placebo-controlled trial designed to estimate the efficacy of MEGF0444A treatment to disease progression, combined with oxaliplatin + folinic acid + 5-Fluorouracil (mFOLFOX-6) + bevacizumab therapy in participants with metastatic colorectal cancer (CRC).
Interventions
- DRUG Bevacizumab
- DRUG Oxaliplatin
- DRUG 5-Fluorouracil
- DRUG Folinic acid
- DRUG MEGF0444A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2011-11 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01399684
The ClinicalTrials.gov registry entry for NCT01399684 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT01399684 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01399684 about?
NCT01399684 is a clinical study titled "A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer". This is a Phase II, multicenter, randomized, double-blind, placebo-controlled trial designed to estimate the efficacy of MEGF0444A treatment to disease progression, combined with oxaliplatin + folinic acid + 5-Fluorouracil (mFOLFOX-6) + bevacizumab therapy in participants with metastatic colorectal ...
What is the current status of trial NCT01399684?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 127 participants. The study started on 2011-11. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01399684?
The interventions under investigation include: Bevacizumab (DRUG), Oxaliplatin (DRUG), 5-Fluorouracil (DRUG), Folinic acid (DRUG), MEGF0444A (DRUG).
Who is sponsoring clinical trial NCT01399684?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.